CN1353185A - Recombinant adenovirus of bone morphogenetic protein and its method for exciting bone generation - Google Patents
Recombinant adenovirus of bone morphogenetic protein and its method for exciting bone generation Download PDFInfo
- Publication number
- CN1353185A CN1353185A CN00127115.6A CN00127115A CN1353185A CN 1353185 A CN1353185 A CN 1353185A CN 00127115 A CN00127115 A CN 00127115A CN 1353185 A CN1353185 A CN 1353185A
- Authority
- CN
- China
- Prior art keywords
- virus
- bone
- bmp
- mesenchymal cell
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 42
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 title claims abstract description 34
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 title claims abstract description 22
- 229940112869 bone morphogenetic protein Drugs 0.000 title claims abstract description 22
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 17
- 210000000988 bone and bone Anatomy 0.000 title claims description 48
- 241000700605 Viruses Species 0.000 claims abstract description 23
- 230000008468 bone growth Effects 0.000 claims abstract description 5
- 241000702421 Dependoparvovirus Species 0.000 claims abstract description 4
- 241001430294 unidentified retrovirus Species 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 71
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 14
- 230000002642 osteogeneic effect Effects 0.000 claims description 14
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 11
- 230000000638 stimulation Effects 0.000 claims description 10
- 239000007943 implant Substances 0.000 claims description 9
- 239000002054 inoculum Substances 0.000 claims description 8
- 239000002243 precursor Substances 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 210000000963 osteoblast Anatomy 0.000 claims description 6
- 230000004069 differentiation Effects 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 3
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 3
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 3
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 3
- 241001135569 Human adenovirus 5 Species 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims description 2
- 230000007547 defect Effects 0.000 claims description 2
- 230000002188 osteogenic effect Effects 0.000 claims description 2
- 230000010076 replication Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 16
- 102000004169 proteins and genes Human genes 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 4
- 241001068295 Replication defective viruses Species 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract 2
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 238000010562 histological examination Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 241000282898 Sus scrofa Species 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 238000010361 transduction Methods 0.000 description 6
- 230000026683 transduction Effects 0.000 description 6
- 230000011164 ossification Effects 0.000 description 5
- 230000003305 autocrine Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000003076 paracrine Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- JYGRAOYMDDFOSM-FQJIPJFPSA-N (4s)-4-[[(2s)-4-carboxy-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]propanoyl]amino]butanoyl]amino]-5-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentano Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN JYGRAOYMDDFOSM-FQJIPJFPSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 108010053500 delicious peptide Proteins 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 108010088237 ATCGAT-specific type II deoxyribonucleases Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 101710167839 Morphogenetic protein Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A method and material for promoting bone growth, that is, a replication-defective virus and the protein in the bone morphogenetic protein family coded by the said virus are disclosed. The said virus is chosen from adenovirus, adeno-associated virus and retrovirus. The masenchyme cell transfected by the said virus, the inoculam containing the mesenchyme cell, and the method for internally and externally promoting bone growth are disclosed.
Description
The present invention relates to biological and medical field, more specifically, the present invention relates to Delicious peptide (bonemorphogenetic protein, BMP) recombinant adenovirus, and stimulate osteogenetic method with described adenovirus.
Bone plays the support effect in Mammals.For various reasons, bone can sustain damage, for example fracture and tumor destruction etc.Therefore need exploitation to stimulate osteogenetic method and associated materials and equipment effectively.
At present clinically, still, implant the method at the position that needs reparation then adopting certain position to gather osseous tissue from patient body.This method makes patient must bear extra operation pain.And in some cases, patient itself can not provide enough osseous tissues to supply to repair the usefulness at position.
Simultaneously, before the present invention, it all is to carry out as follows that the BMP (BoneMorphogenetic Protein) that uses traditional gene engineering method to produce stimulates osteogenesis:
Utilize gene recombination technology at external generation BMP (mainly in the expressing cho cell system) → sneak in solid carrier (as collagen protein sponge) → implant patient or the animal body to stimulate living bone with protein separation technology purifying bmp protein → bmp protein.
Yet, in aforesaid method, exist following shortcoming:
(1) BMP is low in the cell inner expression amount, thereby preparation albumen is with high costs.
(2) meeting quilt enzymolysis/degraded rapidly after bmp protein is inserted in the body, thus lose activity, thereby to reach the required dosage of body endostosis high (bibliographical information is all in the milligram level).This and shortcoming (1) addition cause higher cost.
(3) owing to need solid carrier, therefore must carry out surgical operation and be implanted.In addition, implant site must have physical space to allow solid carrier to put into.This has limited the application of aforesaid method, and patient has also been caused certain pain.
Therefore, this area presses for new effective, the convenient and/or inexpensive osteogenetic method of stimulation and associated materials and equipment for a long time.
An object of the present invention is to provide new effective, the convenient and/or inexpensive osteogenetic method of stimulation.Preferably, this method pain that patient is caused is less than prior art.
Another object of the present invention provides the material that is used for described method.
A further object of the present invention provides bone or the osseous tissue precursor that forms with the inventive method.
In a first aspect of the present invention, a kind of virus of replication defect type is provided, this encoding viral is expressed the albumen in the bone morphogenetic proteins family, and described virus is selected from: adenovirus, adeno associated virus and retrovirus.Preferably, the albumen in the described bone morphogenetic proteins family is selected from: BMP-2, BMP-4, BMP-7.More preferably, the albumen in the described bone morphogenetic proteins family is BMP-2.
In a second aspect of the present invention, a kind of mesenchymal cell of conversion is provided, it expresses the albumen in the bone morphogenetic proteins family.Preferably, this mesenchymal cell be with the present invention above-mentioned virus transform.
In a third aspect of the present invention, a kind of interior inoculum with the stimulation bone growth of mammalian body that is used to implant is provided, this inoculum contains the above-mentioned mesenchymal cell of the present invention.
In a fourth aspect of the present invention, the method of a kind of external generation bone or osseous tissue precursor is provided, it comprises step: under the condition that is fit to the cell growth, cultivate the mesenchymal cell of conversion of the present invention, make it at vitro differentiation osteogenic tissue precursor or osteoblast.
In a fifth aspect of the present invention, a kind of osteogenetic method that stimulates in vivo is provided, it comprises step: the inoculum that the present invention is above-mentioned is implanted the osteogenetic position of needs.
In the accompanying drawing,
Fig. 1 has shown the building process of recombinant adenovirus Adv-BMP2.
Fig. 2 has shown the expression in mesenchymal cell at external Adv-BMP2.
Fig. 3 has shown under external Adv-BMP2 influence, cell proliferation and time relation.
Fig. 4 has shown under external Adv-BMP2 influence, the dependency of cell proliferation and Adv-BMP2 dosage.
Fig. 5 has shown that the mesenchymal cell that infected by Adv-BMP2 raises at vitro culture process neutral and alkali phosphatase activity.
Fig. 6 has shown that the mesenchymal cell that is subjected to the Adv-BMP2 infection at vitro culture 15-20 days, has the sedimentary generation of calcium ion.
Fig. 7 has shown in the mouse of handling with the inventive method, the situation that new bone tissue generates in leg muscle.Wherein Fig. 7 A is no any processing; Fig. 7 B is the untreated cell of injection; Fig. 7 C is the cell that injection Adv-β gal handled; Fig. 7 D is the cell that injection Adv-BMP2 handled.
Fig. 8 is to stimulate the photo of the histological examination of new bone in the mouse muscle that generates with the inventive method.
Fig. 9 has shown the new osteogenetic situation of handling with the inventive method in rabbit backbone position.
Figure 10 is the photo that the new bone of rabbit that forms with the inventive method is carried out histological examination.
Figure 11 has shown new osteogenetic situation between the pig spinal vertebral of handling with the inventive method.Among the figure, filled arrows: cause vertebral fusion up and down with the cell after the Adv-BMP2 conversion; Hollow arrow: do not cause vertebral fusion (no change) up and down with the cell after the Adv-β gal conversion.
Figure 12 is the photo that the new bone of pig that forms with the inventive method is carried out histological examination.Wherein, Figure 12 A display organization is learned and check the visible new osseous tissue that formed between centrum; Figure 12 B has shown the soft tissue between the normal cone.
Detailed Description Of The Invention
Inventive point of the present invention is: adopt the means of transgenosis (gene therapy), between the BMP gene is changed over to In the mesenchymal cell. Utilize mesenchymal cell routinely to produce bmp protein as preparation factory. When changing BMP over to After the mesenchymal cell of gene was placed in the body, the bmp protein that mesenchymal cell produces can stimulate between transduction Mesenchymal cell autocrine stimulation (autocrine) or make that other mesenchymal cell paracrine stimulates in the recipient's body (paracrine), thus make the mesenchymal cell differentiation and development generate new bone.
As used herein, " bone morphogenetic protein (bone morphogenetic protein, BMP) " comprises bone Any member in the morphogenetic proteins family, the BMP gene family has progressively been found 14-15 similar base at present Cause, they all have the function that stimulates bone to generate. Any bmp protein all can be used for the present invention. Preferably, Bone morphogenetic protein is selected from: BMP-2, BMP-4, BMP-7. More preferably, described bone form takes place Albumen is BMP-2.
As used herein, after " replication-defective virus " refers to virus infected cell as carrier, can not the oneself Copy.
As used herein, " mesenchymal cell " refers to various have differentiation and development Gegenbaur's cell, bone precursors Cell, it comprises various stem cells, precursor and common mesenchymal cell.
Any virus that is used as in the art carrier all can be used for the present invention, especially is in gene therapy The virus of using in the field is such as adenovirus, adeno-associated virus and retrovirus. Preferably these viruses are multiple Defective virus processed.
The present invention is applicable to all mammals, comprising (but being not limited to): people, dog, cat, sheep, Ox, horse, pig, tiger etc. The present invention can be used for medical science, veterinary field.
In the present invention, at first make up the carrier that contains the BMP gene. This can finish with conventional method.
After having made up the carrier (as virus) that contains the BMP gene, available routine techniques will contain the virus of BMP gene and the combination of mesenchymal cell, promptly utilize virus vector that the BMP gene is imported mesenchymal cell.This is a very important step of the present invention.With the recipient cell of mesenchymal cell, not only can produce autocrine stimulation and paracrine stimulatory effect as the BMP gene.Simultaneously can produce bmp protein and effect in vivo and in vitro constantly again, thereby the excellent osteogenetic effect of stimulation is provided.
Obtained to change over to after the mesenchymal cell of BMP gene, just can further cultivate and can obtain more cell, perhaps freezing standby, perhaps directly use it for the stimulation osteogenesis.
Stimulate osteogenetic mode that two big classes are arranged.One class is to utilize the vitro tissue engineering.With the above-mentioned mesenchymal cell that changes the BMP gene over to of the present invention, can generate tissue in vitro culture technology by routine.Show, but mesenchymal cell of the present invention differentiation and development in the vitro culture process becomes into osteoblast (osteoblast).In one embodiment of the invention, shown at external bone and the osseous tissue precursor of having formed.
Another kind of is directly to use clinically.It comprises makes a kind of being used to implant in the mammalian body to stimulate the inoculum of bone growth, it has contained the above-mentioned importing of the present invention mesenchymal cell of BMP gene.A kind of example of inoculum is exactly the suspension that contains the mesenchymal cell that has imported the BMP gene.Then,, will need osteogenetic position in the described inoculum implantation mammalian body,, thereby form new bone with the stimulation osteogenesis by for example direct injection or modus operandi.The present invention's range of application clinically can contain Orthopeadic Surgery, plastic surgery and Neurological Surgery, and all use the occasion of osseous tissue, osteogenesis, bone fusion clinically.
Particularly, the present invention has following concrete application scenario:
1, common clinically have a case that can not heal after the fracture.The mesenchymal cell of Adv-BMP2 transduction can be used for being injected directly into not more position, generation autocrine stimulation and paracrine stimulatory effect promotion union of fracture of fracture.
2, often to be used for other operative site on orthopaedics and the orthopedic clinical treatment from patient's certain position intercepting bone on one's body.The inventive method can be save this intercepting bone-operating, reduces patient's misery, especially to can not bear the patient of extra operation more on physical efficiency, provides new treatment machine meeting.
3, after the present invention also was used in the bone tumor operation of orthopaedics and whole surgery, new bone was grown in the symphysis of filling out again at disappearance position.
4, the present invention can be used for the vitro tissue engineering.At the front body structure of external generation bone or osseous tissue, back skeletonization rapidly implants.
5, orthopaedics spinal fusion operation.Traditional method uses steel plate to fix or from the body bone.Present method can be save operation with injection and cause spinal fusion.
6, all use osseous tissue, and the occasion of impelling osseous tissue to generate all can be used the inventive method.
The present invention has following advantage:
(1) must be at vivoexpression and separation and purification bmp protein, thus process and the cost that batch production prepares BMP save.
(2) mesenchymal cell that shifts of receptor gene in vivo external enwergy produce bmp protein constantly and keep lasting biological action, thereby avoided immediately digesting after bmp protein implants in the past the problem of inactivation.
(3) mesenchymal cell after the transgenosis can implant with the method for direct injection or operation, thereby has eliminated the obstacle of necessary use solid carrier, thereby has reduced the restriction of clinical application.In addition, the pain that patient is caused is less than prior art.
(4) adenovirus of taking on transgenosis can cause the intravital immune response of receptor because of the antigenicity of himself, is finally removed.Therefore, avoided the mesenchymal cell after the transgenosis unrestrictedly to stimulate the consequence of giving birth to bone in vivo.
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to normal condition, people such as Sambrook for example, molecular cloning: laboratory manual (NewYork:ColdSpring Harbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.
Embodiment
(1) makes up the recombinant adenovirus that carries the BMP-2 gene
People BMP-2 gene is from ATCC (American type culture collection).With the molecular cloning means people BMP-2 gene is inserted formation plasmid PAC-BMP2 among the expression plasmid PAC.In this plasmid, the BMP-2 gene is subjected to the control of cytomegalovirus early promoter/enhanser (cytomegalovirus, early gene promoter/enhancer).With XhoI PAC-BMP2 is cut into wire.
With adenovirus/5 types (adenovirus type 5) protease K digesting (56 ℃ are spent the night) of purifying preparation, discharge the genomic dna of virus with the degraded coat protein.With the ClaI restriction endonuclease genomic dna of adenovirus is digested (37 ℃, 60 minutes), thus produce one big, little two dna fragmentations.Separating these two fragments with the agar electrophoresis method gathers in the crops big dna fragmentation then and is called the big fragment of ClaI.
With lipofectamine PAC-BMP2 and the big fragment cotransfection of adenovirus ClaI (co-transfection) after the XhoI cutting are gone in 293 cells.Point is got the virus plaque of formation after 10 days.After further plaque purifying and amplification, this recombinant adenovirus is called Adv-BMP2 (building process is seen Fig. 1).
This recombinant adenovirus 5 type Adv-BMP2 are preserved in Chinese typical culture collection center (CCTCC, China, Wuhan City) on July 11st, 2000, and the CCTCC preserving number is V200004.
Embodiment 2
Change the BMP gene over to mesenchymal cell
The adenovirus of reorganization has lost the propagation in ordinary cells and the function of cell killing.Only cell is gone in the BMP-2 transgenosis that it can be carried as carrier.Infect various mesenchymal cells (the medulla mesenchyma cell that comprises mouse C3H10T1/2 cell and rabbit and pig) with Adv-BMP2, then vitro culture 5 days.
The collecting cell nutrient solution carries out immunoprecipitation (immunoprecipitation) back with the antibody of specific anti-human BMP2 and does immunity printing and dyeing (Western blot) test.Visible special BMP-2 band in the cell culture fluid that Adv-BMP2 infects.In other control group, then do not have.This BMP-2 transgenosis that shows the Adv-BMP2 mediation can produce people BMP-2 albumen (Fig. 2) in mesenchymal cell.
Mesenchymal cell after the Adv-BMP2 transfection is at external differentiation and development
After infecting various mesenchymal cells (as mouse, rabbit and pig) with Adv-BMP2, in the vitro culture process, following variation appears in the mesenchymal cell that is contaminted:
A, mesenchymal cell number.7th day comparable contrast mesenchymal cell (untreated mesenchymal cell and non-activity recombinant adenovirus infect mesenchymal cell) the propagation 3 multiple orders (Fig. 3) of mesenchymal cell after propagation is contaminted after cultivation.And the effect of mesenchymal cell propagation be directly proportional with the consumption of Adv-BMP2 (Fig. 4).The Adv-BMP2 consumption is big, and mesenchymal cell propagation is many, otherwise then few.
B, mesenchymal cell differentiation.The mesenchymal cell that infected by Adv-BMP2 can be to becoming osteoblast to break up in the vitro culture process.It is masked as alkaline phosphatase activities and raises.The contrast mesenchymal cell is then kept alkaline phosphatase activity constant (Fig. 5).
C, calcium ion precipitation.The mesenchymal cell that is subjected to the Adv-BMP2 infection can present Van Cossa stained positive at vitro culture 15-20 days, and this indicates the sedimentary generation of calcium ion.This phenomenon is typical external one-tenth osteoblast/osteoblastic another sign.And the contrast mesenchymal cell does not have this reaction (Fig. 6).
Embodiment 4
Mesenchymal cell after the Adv-BMP2 transduction generates new bone in vivo
To can generate new bone in the mesenchymal cell implantation animal body after the Adv-BMP2 transduction, but the method direct injection or the operation of implantation are put into
A, in the mouse body, generate new bone
Three weeks behind the muscle of thigh of the C3H10T1/2 injection cell after the Adv-BMP2 transduction being gone into mouse.X-ray examination can be found new bone (Fig. 7) at the intramuscular of injection site.Further confirm to have complete various osseous tissue forms with histological examination, as osteocyte, chondrocyte, medullary space fine jade (Fig. 8) at the new bone that intramuscular generates.The control group no change.
B, in the rabbit body, generate new bone
When the spinal bone position of self the rabbit bone marrow mesenchymal cell after the Adv-BMP2 transfection being implanted rabbit back with operation method.The visible new osteogenesis (Fig. 9) of the X-ray examination of 4-5 after week.Further complete osseous tissue form (Figure 10) is confirmed in histological examination.The control group no change.
C, in the pig body, generate new bone
When self the Medulla Sus domestica mesenchymal cell after the Adv-BMP2 transduction is implanted space between spinal vertebral with operation method.The back X-ray examination of 6 weeks can be found the new bone (Figure 11) that forms in interbody space.Newly-generated osseous tissue can fuse and causes fusion going up hypocentrum.The histologic characteristics (Figure 11, Figure 12 A and 12B) of new bone is confirmed in histological examination.The interbody space of control group is kept original soft tissue structure.X-ray and histological examination no change.
Should be understood that those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims institute restricted portion equally.
Claims (9)
1. the virus of a replication defect type is characterized in that, the albumen in this encoding viral bone morphogenetic proteins family, and described virus is selected from: adenovirus, adeno associated virus and retrovirus.
2. virus as claimed in claim 1 is characterized in that, the albumen in the described bone morphogenetic proteins family is selected from: BMP-2, BMP-4, BMP-7.
3. virus as claimed in claim 1 is characterized in that the albumen in the described bone morphogenetic proteins family is BMP-2.
4. virus as claimed in claim 1 is characterized in that, described virus is recombinant adenovirus 5 type Adv-BMP2, and the CCTCC preserving number is V200004.
5. the mesenchymal cell of a conversion is characterized in that, it expresses the albumen in the bone morphogenetic proteins family.
6. mesenchymal cell as claimed in claim 5 is characterized in that, it is transformed by the described virus of arbitrary claim among the claim 1-5.
7. one kind is used to implant the interior inoculum with the stimulation bone growth of mammalian body, it is characterized in that it contains the described mesenchymal cell of claim 5.
8. the method for external generation bone or osseous tissue precursor is characterized in that it comprises step: under the condition that is fit to the cell growth, cultivate the described mesenchymal cell of claim 5, make it at vitro differentiation osteogenic tissue precursor or osteoblast.
9. one kind stimulates osteogenetic method in vivo, it is characterized in that it comprises step: the described inoculum of claim 7 is implanted the osteogenetic position of needs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001271156A CN1137993C (en) | 2000-11-02 | 2000-11-02 | Recombinant adenovirus of bone morphogenetic protein and its method for exciting bone generation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001271156A CN1137993C (en) | 2000-11-02 | 2000-11-02 | Recombinant adenovirus of bone morphogenetic protein and its method for exciting bone generation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1353185A true CN1353185A (en) | 2002-06-12 |
| CN1137993C CN1137993C (en) | 2004-02-11 |
Family
ID=4592134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB001271156A Expired - Lifetime CN1137993C (en) | 2000-11-02 | 2000-11-02 | Recombinant adenovirus of bone morphogenetic protein and its method for exciting bone generation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1137993C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004083434A1 (en) * | 2003-03-17 | 2004-09-30 | The University Of Hong Kong | A combined adeno-associated virus and adenovirus cocktail gene delivery system for high effiency gene expression without eliciting immune response in immuno-competent subjects |
| CN100402654C (en) * | 2003-02-19 | 2008-07-16 | 株式会社载体研究所 | Method of treating ischemic disease |
| CN100418582C (en) * | 2005-11-25 | 2008-09-17 | 上海第二医科大学附属第九人民医院 | Microcapsule for promoting bone regeneration and its use |
| CN101564555B (en) * | 2009-05-27 | 2013-01-23 | 深圳市第二人民医院 | Tissue engineering bone implant and method for constructing the same |
| CN114874312A (en) * | 2015-11-16 | 2022-08-09 | Ubi蛋白公司 | Method for extending protein half-life |
-
2000
- 2000-11-02 CN CNB001271156A patent/CN1137993C/en not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100402654C (en) * | 2003-02-19 | 2008-07-16 | 株式会社载体研究所 | Method of treating ischemic disease |
| WO2004083434A1 (en) * | 2003-03-17 | 2004-09-30 | The University Of Hong Kong | A combined adeno-associated virus and adenovirus cocktail gene delivery system for high effiency gene expression without eliciting immune response in immuno-competent subjects |
| CN100418582C (en) * | 2005-11-25 | 2008-09-17 | 上海第二医科大学附属第九人民医院 | Microcapsule for promoting bone regeneration and its use |
| CN101564555B (en) * | 2009-05-27 | 2013-01-23 | 深圳市第二人民医院 | Tissue engineering bone implant and method for constructing the same |
| CN114874312A (en) * | 2015-11-16 | 2022-08-09 | Ubi蛋白公司 | Method for extending protein half-life |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1137993C (en) | 2004-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Okubo et al. | Osteoinduction by recombinant human bone morphogenetic protein‐2 at intramuscular, intermuscular, subcutaneous and intrafatty sites | |
| Dupont et al. | Synthetic scaffold coating with adeno-associated virus encoding BMP2 to promote endogenous bone repair | |
| Kim et al. | Promising efficacy of Escherichia coli recombinant human bone morphogenetic protein-2 in collagen sponge for ectopic and orthotopic bone formation and comparison with mammalian cell recombinant human bone morphogenetic protein-2 | |
| Murata et al. | Acid‐insoluble human dentin as carrier material for recombinant human BMP‐2 | |
| CN1951964B (en) | Long chain recombinant human bone morphogenesis protein-2 and its preparation method and uses | |
| Oliveira et al. | Engineering endochondral bone: in vivo studies | |
| Eriksson et al. | S53P4 bioactive glass scaffolds induce BMP expression and integrative bone formation in a critical-sized diaphysis defect treated with a single-staged induced membrane technique | |
| US9585764B2 (en) | Bone implant device | |
| Pensak et al. | Gene therapy for bone regeneration | |
| US20120277879A1 (en) | Osteogenic device for inducing bone formation in clinical contexts | |
| Evans et al. | Orthopaedic gene therapy: Twenty-five years on | |
| Vandersteenhoven et al. | Histological investigation of bone induction by demineralized allogeneic bone matrix: a natural biomaterial for osseous reconstruction | |
| CN1137993C (en) | Recombinant adenovirus of bone morphogenetic protein and its method for exciting bone generation | |
| US20120263692A1 (en) | Engineered Xenogeneic Cells for Repair of Biological Tissue | |
| Yukna et al. | Comparative evaluation of decalcified and non‐decalcified freeze‐dried bone allografts in rhesus monkeys. I. Histologic findings | |
| Machtei et al. | The use of endothelial progenitor cells combined with barrier membrane for the reconstruction of peri‐implant osseous defects: an animal experimental study | |
| Lin et al. | Augmentation of osseous phenotypes in vivo with a synthetic peptide | |
| CN1232310C (en) | Endoprosthesis with long-term stability | |
| WO1998030234A1 (en) | Compositions for osteogenesis and chondrogenesis | |
| CN1656223A (en) | Bone generation by gene therapy | |
| Han et al. | Ectopic osteogenesis by ex vivo gene therapy using beta tricalcium phosphate as a carrier | |
| DE69324345T2 (en) | EXPRESSION OF OSTEOGENIC FACTOR OP-1 IN SPODOPTERA FRUGIPERDA CELLS INFECTED WITH RECOMBINANT BACULOVIRUS | |
| Xu et al. | The osteoinductive effect of nano-nacre particles on MC-3T3 E1 preosteoblast through controlled release of water soluble matrix and calciumions | |
| JPH06340555A (en) | Pulp-capping agent enabling formation of dentine | |
| El-Gindy et al. | Cell therapy: A potential solution for the healing of bone cavities |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANGHAI ANJIU BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: SHANGHAI ZHAO'AN MEDICAL TECHNOLOGY CO., LTD. Effective date: 20100402 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200021 ROOM 2005,SOUTH TOWER, HONGKONG PLAZA, NO.283, HUAIHAI MIDDLE ROAD, SHANGHAI CITY TO: 201108 FLOOR 2, BUILDING 3, NO.4299, JINDU ROAD, SHANGHAI CITY |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100402 Address after: 201108, No. 3, 4299 Jin Lu, building 2, Shanghai Patentee after: Shanghai Anjiu Biotechnology Co.,Ltd. Address before: 2005, room 200021, South, Hongkong square, 283 Huaihai Road, Shanghai Patentee before: Zhaoan Medical Science & Tech Co.,Ltd. Shanghai |
|
| ASS | Succession or assignment of patent right |
Owner name: ZHAO-AN MEDICAL SCIENCE + TECH. CO., LTD., SHANGHA Free format text: FORMER OWNER: SHANGHAI ANJIU BIOTECHNOLOGY CO., LTD. Effective date: 20131113 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201108 MINHANG, SHANGHAI TO: 200080 HONGKOU, SHANGHAI |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20131113 Address after: 200080 room 289, 1725 Wujin Road, Shanghai Patentee after: Zhaoan Medical Science & Tech Co.,Ltd. Shanghai Address before: 201108, No. 3, 4299 Jin Lu, building 2, Shanghai Patentee before: Shanghai Anjiu Biotechnology Co.,Ltd. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160527 Address after: 201108, No. 3, building 4299, Jin Du Road, Shanghai, Minhang District Patentee after: Shanghai Anjiu Biotechnology Co.,Ltd. Address before: 200080 room 289, 1725 Wujin Road, Shanghai Patentee before: Zhaoan Medical Science & Tech Co.,Ltd. Shanghai |
|
| CX01 | Expiry of patent term |
Granted publication date: 20040211 |
|
| CX01 | Expiry of patent term |